DOCSLIB.ORG

EQUILIBRIUM-10 LINE the Authentic Expression of Balance in Your Skin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EQUILIBRIUM-10 LINE the Authentic Expression of Balance in Your Skin 01 EQUILIBRIUM-10 LINE The authentic expression of balance in your skin EQUILIBRIUM-10 LINE FIRST STEP TO BEAUTY Its effectiveness is immediate in the recovery of your skin’s optimum pH, and the balance of dry or oily skin. 01. Oxygenating The activity of cells receiving oxygen triples and cell division increased by 20%. 02. Restructuring increases cell activity, encouraging the elasticity of youthful skin. 03. Hydrating A balancing effect on the mantle, smoothing and closing pores. EQUILIBRIUM-10 LINE ACTIVE INGREDIENTS AQUAXTREM TM Placebo 25 AQUAXTREM™ 20 • Activates the own mechanisms of the skin for a long-lasting moisturization. + 11,6 % + 9,6 % • Skin hydration from the inside. 15 • Stratum corneum resistance and cohesion. • Improvement of barrier function and NMF. 10 • Complementary activity: anti-aging. % increase in hydration % increase in hydration 5 0 D29 D31 Increase of AQUAXTREM™ and placebo as compared to control WRINKLES CITRUSTEM™ Product T0 T56 % Decrease Placebo 3,58 3,47 3,17* • Organizes and redensifies dermis structure. CITRUSTEM™ (3%) 3,54 3,19 9,89* • Repairs extracelular matrix. CITRUSTEM™ (placebo) 3,54 3,19 6,7* • Result: Firmer skin. * Statistically significant (Wilcoxon, p<0.05) • Recovers the elasticity of 12 years ago. EQUILIBRIUM-10 LINE 01 BALANCING DERMO-PROTECTIVE FLUID ACTION It contains sweet almond oil and eucalyptus, which give it soothing, softening and anti-inflammatory properties. It cleanses and balances skins of all types, eliminating impurities and respecting the integrity of the epicutaneous mantle that protects the skin. HOW TO USE Apply the product with circular movements to clean the face and neck. Remove with a damp towel, dry the skin and apply the corresponding lotion. INGREDIENTS Aqua, Caprylic/Capric Triglyceride, Cetyl Alcohol, Stearyl Alcohol, Glycerin, Ceteareth-20, Phenoxyethanol, Alcohol, Peg-7 Glyceryl Cocoate, Propylene Glycol, Prunus Amygdalus Dulcis Oil, Parfum, Eucalyptus Globulus Leaf Extract, Ethylhexylglycerin, Linalool, Geraniol, Bht. SKIN PROFILE All skin types. SIZE 200 ml / 500 ml REFERENCE EB00355 / EB01568 SYNERGY Balancing Hydra Global Lotion. EQUILIBRIUM-10 LINE 01 BALANCING DERMO-PROTECTIVE FLUID COMPOSITION SWEET ALMOND. Skin moisturizing and conditioning. Improves skin barrier function. EUCALYPTUS. Astringent. Seboregulating. Epithelizing. Deodorant. Antiseptic. Purifying. Anti-inflammatory. Wound healing agent. EQUILIBRIUM-10 LINE 02 SENSITIVE DERMO-PROTECTIVE FLUID ACTION It contains biomolecular plant extracts that cleanse in depth, meanwhile removing detritus, but without damaging the epidermis or altering the pH of the acid mantle of the skin. It brings moisture and elasticity to the skin. HOW TO USE Apply the product with circular movements to clean the face and neck. Remove with a damp towel, dry the skin and apply the corresponding lotion. INGREDIENTS Aqua, Caprylic/Capric Triglyceride, Cetyl Alcohol, Stearyl Alcohol, Propylene Glycol, Ceteareth-20, Phenoxyethanol, Glycerin, Dimethicone, Peg-7 Glyceryl Cocoate , Glucose, Sodium Pca, Parfum, Ethylhexylglycerin, Glutamic Acid, Glycine, Lactic Acid, Lysine, Urea, Hexyl Cinnamal, Allantoin, Arnica Montana Flower Extract, Cucumis Sativus Fruit, Hedera Helix Leaf Extract, Malva Sylvestris Flower Extract, SKIN PROFILE Parietaria Officinalis Extract, Sambucus Nigra Flower Extract, Tilia Platyphyllos Flower Extract, Potassium Sorbate, Sodium Benzoate, Bht. Sensitive skin. SIZE 200 ml / 500 ml REFERENCE EB01563 / EB01566 SYNERGY Sensitive Hydra Global Lotion. EQUILIBRIUM-10 LINE 02 SENSITIVE DERMO-PROTECTIVE FLUID COMPOSITION MOISTURIZING FACTOR POLYPLANT MOISTURIZING · SODIUM PCA. This is a moisturizing molecule that increases the water fixation · IVY. It is a strong regenerator,vessel-protector and venotonic. Anti-cellulite. capacity. It enhances skin moisture, smoothness and elasticity without producing Anti-inflammatory. Purifying. Reduces hydrolipidic accumulation. irritation. · ARNICA. Venotonic and vessel-protection. Anti-inflammatory. Anti-cellulite. · GLUCOSE. It is the main source of energy to activate cellular metabolism. Anti-aging. Antiseptic. In cosmetics it is used as a softener and mainly as anti-aging agent. It also reduces the damage caused by sunlight. · ELDER TREE. Antioxidant. Anti-aging. Photoprotection. Anti-inflammatory. Anti-irritant. Vessel-protection and venotonic. Blood flow activator. · UREA. Urea is considered the best natural moisturizer because of its ability to capture water (hygroscopic action). Furthermore, it has mild keratolytic effects, thus reducing the It is recommended in allergic skins for its soothing and anti-inflammatory thickness of the horny layer and restoring the hydration-evaporation process to normal. · MALLOW. effect.TEWL regulating. Moisturizing. Emollient. Venotonic and vessel-protection. Blood circulation stimulation. Decongestant. · GLUTAMIC ACID. It is one of the most abundant amino acids in the body and a hidden card for the exchange of energy between tissues. It helps to improve the tone Removes impurities. Soothing, Antioxidant. Astringent. Moisturizers. and smooth wrinkles. · LIME TREE. Softener. · LYSINE. It is an essential amino acid that participates in the repair and growth of Regulation of skin moisturization. Refreshing. Stimulant. Revitalizing. tissues and the proper use of fatty acids for the regeneration of energy to the tissue. · CUCUMBER. Anti-aging. · GLYCINE. An amino acid neurotransmitter involved in the processes of collagen and Improves wound healing, preventing it from being infected, regenerates energy synthesis. · PARIETARIA. and moisturizes. · ALLANTOIN. Its main function is cell stimulation and improving tissue reconstruction. · LACTIC ACID. The chemical structure of α-hydroxy acids (AHA) includes multiple hydroxyl groups, which allow for higher water retention and absorption. Thus, these highly hygroscopic compounds boost skin moisturizing and strengthen the skin barrier function. AHAs have regulatory properties on keratinization. EQUILIBRIUM-10 LINE 03 FORTE PLUS DERMO-PROTECTIVE FLUID ACTION Dermo-protective fluid that cleans and removes make-up in depth. It has a dermo-purifying effect that normalizes the sebaceous and antiseptic secretion (reduction of bacteria) thanks to the action of the ester of Malic (apple) acid, whose properties are moisturizing, keratolytic (desquamating), anti-acne and anti-aging. It can be used as a skin exfoliant, closing pores, and increasing the softness of skin while limiting the signs of wrinkles and expression lines by its chelating action. Recommended for oily skin and skin with a tendency to acne. HOW TO USE Apply the product with circular movements to clean the face and neck. Remove with a damp towel, dry the skin and apply the corresponding lotion. INGREDIENTS Aqua, Caprylic Capric Triglyceride, Cetearyl Alcohol / Ceteareth 20, Di-C12-13 Alkyl Malate, Propylene Glycol, SKIN PROFILE Aqua/ Propylene Glycol/ Sodium PCA/ Glucose/ Urea/ Glutamic Acid/ Lysine/ Glycine/ Allantoin/ Lactid Acid, Oily skin and acneic skin. Phenoxyethanol/Ethylhexylglycerin, Peg - 7 Glyceryl Cocoate, Dimethicone, B.H.T, Parfum, Hexyl Cinnamal, Butylphenyl Methylpropional, Geraniol, Citronellol, Linalool. SIZE 200 ml REFERENCE EB01564 SYNERGY Forte Plus Hydra Global Lotion. EQUILIBRIUM-10 LINE 03 FORTE PLUS DERMO-PROTECTIVE FLUID COMPOSITION COSMACOL® 5%. Cosmacol EMI is a non greasy lipid, very similar to the hydro- MOISTURIZING FACTOR lipidic cutaneous layer. This product shows outstanding moisturizing properties providing a benefit in treatment of aged skin as well as greasy skin as a sebum regulator. · SODIUM PCA. This is a moisturizing molecule that increases the water fixation This ester provides a rich texture without leaving a greasy feeling on the skin. capacity. It enhances skin moisture, smoothness and elasticity without producing irritation. POLYPLANT MOISTURIZING · UREA. Urea is considered the best natural moisturizer because of its ability to capture water (hygroscopic action). Furthermore, it has mild keratolytic effects, thus reducing the · IVY. It is a strong regenerator,vessel-protector and venotonic. Anti-cellulite. Anti-inflammatory. Purifying. Reduces hydrolipidic accumulation. thickness of the horny layer and restoring the hydration-evaporation process to normal. · GLUTAMIC ACID. It is one of the most abundant amino acids in the body and a · ARNICA. Venotonic and vessel-protection. Anti-inflammatory. Anti-cellulite. hidden card for the exchange of energy between tissues. It helps to improve the tone Anti-aging. Antiseptic. and smooth wrinkles. Antioxidant. Anti-aging. Photoprotection. Anti-inflammatory. Anti-irritant. · ELDER TREE. · LYSINE. It is an essential amino acid that participates in the repair and growth of Vessel-protection and venotonic. Blood flow activator. tissues and the proper use of fatty acids for the regeneration of energy to the tissue. · MALLOW. It is recommended in allergic skins for its soothing and anti-inflammatory · GLYCINE. An amino acid neurotransmitter involved in the processes of collagen and effect.TEWL regulating. Moisturizing. Emollient. Venotonic and vessel-protection. Blood energy synthesis. circulation stimulation. Decongestant. · ALLANTOIN. Its main function is cell stimulation and improving tissue reconstruction. · LIME TREE. Removes impurities. Soothing, Antioxidant. Astringent. Moisturizers. Softener. · LACTIC ACID. The chemical structure of α-hydroxy acids (AHA) includes multiple hydroxyl groups, which allow for higher water retention and
Load more

Recommended publications
  • Novel Derivatives of Bio-Affecting Phenolic Compounds and Pharmaceutical Composition Containing Them
    Europaisches Patentamt European Patent Office © Publication number: 0046 270 A1 Office europeen des brevets ™ EUROPEAN PATENT APPLICATION @ Application number: 81106277.7 © Int. CI.3: C 07 C 103/78, C 07 C 93/26, C 07 C 69/24, C 07 C 1 53/07, @ Date of filing: 12.08.81 C07C 69/28 // C07C1 25/065 <§) Priority: 13.08.80 US 177825 © Applicant: INTERx RESEARCH CORPORATION, 2201 West 21 st Street, Lawrence Kansas 66044 (US) © I nventor : Bodor, Nicholas S., 31 5 Southwest 91 st Street, ® Dateofpublicationofapplication:24.02.82 S^^S^mHariMBM Bulletin m/b Terrace, Gainesville, Florida 32605 (US) Inventor: Pogany, Stefano A., 520 Louisiana Street, Lawrence Kansas 66044 (US) @ Designated Contracting States : AT BE CH DE FR GB IT ® Representative: Abitz, Walter, Dr.-lng. et al, Abitz, Mori, LI LU NL SE Gritschneder P.O. Box 86 01 09, D-8000 Munchen 86 (DE) Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them. Novel@ Novel transient prodrug forms of bio-affecting phe- amyl, CH2ONO2,CH2ON02, -CH2OCOR2 or any non-heterocyclic nolic compounds are selected from the group consisting of member of the group defined by R2Rz above; and n.isn is at least those having the structural formula (I): one and equals the total number of phenolic hydroxyl functions comprising the non-steroidal bioaffecting phenol o etherified via a R2COXCH(R3)0-moiety; those having the structural formula (II): R2-C-X-CH-0- (I) I O R, II R2-C-X-CH-0- -RM-i-O-C-R2 (II) wherein X is O, S or NR5 wherein R5 is hydrogen or lower alkyl;alky!;
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • China Japan United States Europe
    Inhibitor United States China Toll Free: +1 877 796-6397 Toll Free: 400-668-6834 Fax: +1 832 582-8590 Fax: 021-68591981 E-mail: [email protected] E-mail: [email protected] Europe Japan Tel: +49-89-46148500 Tel: + 81 3-5632-9610 Fax: +49-89-461485022 Fax: + 81 3-5632-9619 E-mail: [email protected] E-mail: [email protected] Protein Tyrosine Kinase PI3K/Akt/mTOR MAPK Inhibitors Cytoskeletal Signaling Selleck Chemicals supplies over 3,000 Apoptosis + inhibitors used in the study of cell 3000 Epigenetics Cell Cycle Inhibitors signaling pathways. Ubiquitin Signaling DNA Damage Stem Others Cells Neuronal Signaling Product Citations Selleck products have been cited in more than 12000 studies from various SCI journals. (Cell, Nature, Science: 61 studies) Compound Libraries Bioactive Compound Library 2659 compounds Nature. 2017, 541(7638):481-487. Nature. 2015, 521(7552):357-61. Science. 2016, 354(6315). Nature. 2017, 10.1038/nature21064. Nature. 2015, 521(7552):316-21. Science. 2016, 353(6302):929-32. Kinase Inhibitor Library Nature. 2016, 540(7631):119-123. Nature. 2015, 520(7549):683-7. Science. 2016, 352(6283):353-8. 430 inhibitors Nature. 2016, 539(7629):437-442. Nature. 2015, 520(7547):368-72. Science. 2016, 352(6282):189-96. Nature. 2016, 539(7628):304-308. Nature. 2015, 519(7543):370-3. Science. 2016, 351(6277):aad3680. FDA-approved Drug Library 1443 compounds Nature. 2016, 539(7627):54-58. Nature. 2015, 518(7538):254-7. Science. 2013, 341(6146):651-4. Nature. 2016, 538(7626):477-482. Nature. 2015, 517(7536):583-8.
    [Show full text]
  • Design Cosmetic Ingredients El Camp De Bossa - Les Tallades - La Figuerassa - El Pouet De Tomàs
    biogründl gründl bio biogründl factory Polígono Les Fallulles, nave 34 - sector 2 - 08620 Sant Vicenç dels Horts. Barcelona (SPAIN) Tel. +34 93 660 55 12 - Fax +34 93 660 55 13 - www.biogrundl.es biogründl station design cosmetic ingredients El Camp de Bossa - Les Tallades - La Figuerassa - El Pouet de Tomàs. Tarragona (SPAIN) biogründl factory Polígono Les Fallulles, nave 34 - sector 2 Sant Vicenç dels Horts Barcelona (SPAIN) biogründl station El Camp de Bossa, Les Tallades, La Figuerassa, El Pouet de Tomàs Tarragona (SPAIN) biogründl, s.l., a company located in Barcelona, whose activity is l+D+i and production in the field of active and auxiliary substances which are completely new for cosmetic industry. biogründl, s.l. was founded in 2002 being supported by a great human team with large technical and commercial experience. biogründl, s.l. is filling the gap in the area of cosmetic and dermatologic active substances, which was mainly the field for great sized companies engaged in the commercialization of many products involved in several fields of the chemical industry. Opposite to this concept, biogründl, s.l. has to do exclusively with substances destined to Cosmetology and Dermatology. biogründl, s.l. has acquired in 2012 ten Ha of land, biogründl station, in Tarragona (Spain), which is used to ecological plantation to obtain their own vegetable actives. This way, biogründl, s.l. ensures the origin and the obtaining of such actives. Its market strategy is based on the following concepts: • Contribution of new concepts in formulations to satisfy the proactive demands of Cosmetics. • Fast and dynamic response to customers’ need with the corresponding personal assistance.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0183528A1 Maloney Et Al
    US 20100183528A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0183528A1 Maloney et al. (43) Pub. Date: Jul. 22, 2010 (54) ACNETREATMENT POWDER FOUNDATION Publication Classification (75)75) invenorInventors: Johnobtainstity. D. Malonev, Salisburv. NC (51) A61KInt. Cl. 8/368 (2006.01) Davidson NC (US) s A61O 1704 (2006.01) s A61O I/00 (2006.01) Correspondence Address: A6IP 7/10 (2006.01) INTELLECTUAL PROPERTY f TECHNOLOGY LAW (52) U.S. Cl. .......................................................... 424/60 PO BOX 14329 RESEARCH TRIANGLE PARK, NC 27709 (US) (57) ABSTRACT (73) Assignee: HARMONY LABORATORIES, Dry powder foundation formulations that include a sustained INC., Kannapolis, NC (US) release salicylic acid composition, an effective, buffering amount of one or more Salicylate ions, and one or more of Zinc (21) Appl. No.: 12/639,851 and titanium oxides, and pigments or colorants, are disclosed. 1-1. The formulations provide both acne treatment and preven (22) Filed: Dec. 16, 2009 tion, and Sunblock protection. The formulation can also O O include other Sunblocking or Sunscreen agents to prevent Related U.S. Application Data photoaging and Sunburn, such as avobenzone, and 3-ben (60) Provisional application No. 61/138.436, filed on Dec. Zophenone, and other cosmetically-acceptable active agents 17, 2008. and excipients. US 2010/0183528 A1 Jul. 22, 2010 ACNE TREATMENT POWDER FOUNDATION used as a foundation that provides both acne treatment and prevention and Sunblock protection. CROSS-REFERENCE TO RELATED 0007 Because the composition provides salicylic acid in APPLICATION the form of a Sustained-release composition, the salicylic acid remains effective for an extended period of time.
    [Show full text]
  • Fragances Extracts
    PERSONAL CARE extracts petroleum jellies and paraffins active ingredients antioxidants hair conditioners oils amino acids colourants emollients preservatives fragances vitamins emulsifiers fatty alcohols sunscreens multifunctionals waxes pearl shine concentrates moisturisers opacifiers At Escuder, we are specialists in distributing raw materials aimed primarily at the cosmetics, pharmaceutical, veterinary, food and dietary industries. Since 1896, our aim has been to provide the highest quality in our services and products. Escuder is a dynamic company, with a highly specialised team and all the necessary resources to constantly update our processes and incorporate new tools which enable us to establish close connections with our customers and suppliers. Our extensive experience, sound industry knowledge, reliability and professionalism allow us to adapt to our customers’ needs, providing the highest levels of quality and safety in managing the products and services we offer. This is our catalogue of products aimed primarily at the cosmetics industry. Here you will find a wide range of materials which we hope will be of interest to you and meet your needs. Actives 4-7 Amino Acids 7 Antibacterials, Antifungals 8 Antioxidants 8 Emollients 8-9 Emulsifiers / Fatty Alcohols 10-11 Exfoliants 11 Extracts 12 Fragrances 12 Hair Conditioners 13 Humectants 14 Oils 14-15 Pearl Shine Concentrates / Opacifiers 15 Ph Regulators 15 Preservatives 16 Rheological Modifiers 17 Sequestrant Agents 17 Solubilizers 17 Sunscreen Filters 18 Surfactants 18-19 Sweeteners
    [Show full text]
  • High-Value Oxy-Pharmaceuticals from P450 BM3 ‘Gatekeeper’ Mutations
    High-value oxy-pharmaceuticals from P450 BM3 ‘gatekeeper’ mutations A thesis submitted to The University of Manchester for the degree of Doctor of Philosophy in the Faculty of Science and Engineering 2018 Laura N. Jeffreys School of Chemistry BLANK PAGE 2 Table of Contents Figures……. ………………………………………………………………………………..8 Tables……………………………………………………………………………………...10 Supplementary Figures………………………………………………………………….. 11 List of Abbreviations…………………………………………………………………….. 13 Abstract…………………………………………………………………………………... 15 Acknowledgements ………………………………………………………………………16 Declaration……………………………………………………………………………….. 17 Copyright Statement…………………………………………………………………….. 18 Preface to the Journal Format Thesis………………………………………………….. 19 Author contributions……………………………………………………………………. 21 Chapter 1: General Introduction……………………………………………………... 23 1.1. An Overview of Cytochromes P450……………………………………... 23 1.1.1. The Evolution and Nomenclature of Cytochromes P450…………….23 1.1.2. The History of Cytochrome P450 Research ………………………….28 1.1.3. The P450 Catalytic Cycle …………………………………………….32 1.1.4. The Structure of P450 Enzymes ……………………………………...38 1.1.5. Unusual P450 Proteins ……………………………………………….43 1.2. The Natural Fusion Protein P450 BM3 (CYP102A1) ……………………47 1.2.1. The Structure of P450 BM3 ………………………………………….48 1.2.2. Electron Transfer Within P450 BM3 ………………………………...54 1.2.3. P450 BM3 Mutagenesis and the Gatekeeper Mutants ……………….58 1.3. Real-World Applications of P450 Enzymes ……………………………...61 1.3.1. Using P450 BM3 in the Pharmaceutical Industry ……………………63 1.3.2. Using other P450
    [Show full text]
  • Sensibilisation Aux Drogues Chimiothérapeutiques Des Tumeurs P53 Négatives Par Activation De La Phosphatase Wip1 Victor Clausse
    Sensibilisation aux drogues chimiothérapeutiques des tumeurs P53 négatives par activation de la phosphatase Wip1 Victor Clausse To cite this version: Victor Clausse. Sensibilisation aux drogues chimiothérapeutiques des tumeurs P53 négatives par activation de la phosphatase Wip1. Sciences agricoles. Université Bourgogne Franche-Comté, 2017. Français. NNT : 2017UBFCI002. tel-02094528 HAL Id: tel-02094528 https://tel.archives-ouvertes.fr/tel-02094528 Submitted on 9 Apr 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE DE BOURGOGNE FRANCHE-COMTE UFR Sciences de la Vie, Terre et Environnement Ecole doctorale Environnements - Santé THÈSE Présentée pour l’obtention du titre de DOCTEUR DE L’UNIVERSITE DE BOURGOGNE FRANCHE-COMTE Discipline : Biochimie et Biologie Moléculaire SENSIBILISATION AUX DROGUES CHIMIOTHERAPEUTIQUES DES TUMEURS P53-NEGATIVES PAR ACTIVATION DE LA PHOSPHATASE WIP1 Présentée et soutenue par Victor CLAUSSE Le 22 Mars 2017 Membres du jury : Pr Marc Bardou .........................................................................
    [Show full text]